HCA / HCA Healthcare, Inc. (NYSE) - Forecast, Price Target, Estimates, Predictions

HCA Healthcare, Inc.
US ˙ NYSE ˙ US40412C1018

Projected Stock Price
$401.44 ↓-2.47%

Estimated share price by September 3, 2026.

Projected Revenue

20,343  MM ↑9.34%

Estimated quarterly revenue by December 31, 2026.

Projected Earnings Per Share

9.29 ↑34.45%

Estimated quarterly earnings by December 31, 2027.

Price Target

The average one-year price target for HCA Healthcare, Inc. is $401.44. The forecasts range from a low of $319.61 to a high of $466.20.

Update Frequency: Monthly

Record Date Projection Date High Low Median Average
2025-09-03 2026-09-03 466.20 319.61 408.00 401.44
Stock Upgrades/Downgrades

This card shows analyst upgrades/downgrades for HCA Healthcare, Inc.. An analyst rating is a classification that gives investors a sense of analyst sentiment about the direction and performance of an equity - usually a stock - over a period of time, typically 12 months.

The standard analyst ratings are generally as follows:
  • Buy/Overweight/Outperform - Any of these ratings conveys an analyst’s belief that the stock is likely to outperform a market index (e.g. the S&P 500).
  • Hold/Equal-Weight/Market Perform - Any of these ratings conveys an analyst’s belief that the stock is likely to perform in line with a market index.
  • Sell/Underweight/Underperform - Any of these ratings suggest that an analyst believes the stock is likely to underperform a market index.

When an analyst upgrades a stock, they are signaling that the company’s fundamentals are being undervalued by investors. It could also mean they believe the market is underestimating the company’s potential. The opposite is true when a stock receives a downgrade.

The average rating of each individual analyst’s rating is the consensus rating for a stock. This gives investors a broader sense of the overall sentiment for that stock.

Why Are Analyst Ratings important?

In addition to being able to interpret financial data, stock analysts have connections within the companies they cover that give them access to information retail investors do not have.

Therefore, analyst ratings can help you find opportunities in the market. However, they are guidelines more than recommendations. This is why it’s important to look at analyst ratings over a period of time.

If analysts change their ratings frequently, you should pay close attention to the company’s fundamentals. For example, has there been a significant change to the company’s earnings growth and/or debt?

You should also pay attention to the number of analysts covering a stock over the course of a year. In general, the more analysts who cover the stock give the consensus rating more credibility, but each individual rating less overall weight.

How to Use Analyst Ratings ?

Analyst ratings are one data point for you to consider. Here are some strategies you can use to fine tune your research.

Look at more than one analyst and don’t hesitate to look at analysts that have differing views. This can help challenge any preconceived ideas you have about a stock and point out ways in which your thesis for owning or avoiding a stock may have changed.

Compare a stock’s rating with other stocks in its industry or sector. In some cases, a stock is simply superior to others in its sector. However, at other times, it could be overvalued based on investor sentiment instead of fundamentals.

How are the Fintel Analyst Ratings different?

Analyst ratings by Fintel are presented in close to real-time to stay ahead of generalized information flow. Combined with target price estimates and revenue estimates for the company you have greater accuracy despite market volatility.

Date Analyst Prior Latest
Recommendation
Action
2023-01-19 Oppenheimer Outperform Maintains
2023-01-13 UBS Buy Maintains
2022-12-16 SVB Leerink Outperform Maintains
2022-12-14 Mizuho Buy Maintains
2022-12-12 Goldman Sachs Buy Maintains
2022-11-02 Mizuho Buy Maintains
2022-10-26 Citigroup Buy Maintains
2022-10-25 Raymond James Outperform Maintains
2022-10-24 Wells Fargo Equal-Weight Maintains
2022-10-24 SVB Leerink Outperform Maintains
2022-10-24 Stephens & Co. Overweight Maintains
2022-10-24 RBC Capital Outperform Maintains
2022-10-24 Oppenheimer Outperform Maintains
2022-09-16 Raymond James Outperform Maintains
2022-08-24 SVB Leerink Outperform Maintains
2022-08-02 Mizuho Buy Maintains
2022-07-28 Wells Fargo Equal-Weight Maintains
2022-07-26 Raymond James Outperform Maintains
2022-07-25 Truist Securities Buy Maintains
2022-07-25 SVB Leerink Outperform Maintains
2022-07-25 RBC Capital Outperform Maintains
2022-07-25 Credit Suisse Outperform Maintains
2022-07-15 SVB Leerink Outperform Maintains
2022-07-12 Goldman Sachs Buy Maintains
2022-07-11 Raymond James Outperform Maintains
2022-07-07 Deutsche Bank Buy Maintains
2022-07-06 BMO Capital Market Perform Underperform Downgrade
2022-07-01 Mizuho Buy Maintains
2022-06-21 RBC Capital Outperform Maintains
2022-06-17 Loop Capital Buy Initiate
2022-05-27 Bernstein Market Perform Outperform Upgrade
2022-05-03 Mizuho Buy Maintains
2022-04-26 UBS Buy Maintains
2022-04-26 Raymond James Outperform Maintains
2022-04-25 Wells Fargo Equal-Weight Maintains
2022-04-25 Truist Securities Buy Maintains
2022-04-25 SVB Leerink Outperform Maintains
2022-04-25 RBC Capital Outperform Maintains
2022-04-25 Credit Suisse Outperform Maintains
2022-04-25 Citigroup Buy Maintains
2022-03-29 Wells Fargo Equal-Weight Initiate
2022-01-28 SVB Leerink Outperform Maintains
2022-01-28 Cowen & Co. Outperform Maintains
2022-01-05 Truist Securities Buy Maintains
2021-12-21 JP Morgan Overweight Neutral Downgrade
2021-12-20 Mizuho Buy Maintains
2021-10-26 Raymond James Outperform Maintains
2021-10-25 Stephens & Co. Overweight Maintains
2021-10-25 RBC Capital Outperform Maintains
2021-10-25 Oppenheimer Outperform Maintains
2021-10-25 Credit Suisse Outperform Maintains
2021-10-25 Citigroup Neutral Maintains
2021-09-27 SVB Leerink Outperform Initiate
2021-09-10 Cowen & Co. Outperform Initiate
2021-08-12 Barclays Overweight Equal-Weight Downgrade
2021-08-06 Goldman Sachs Buy Maintains
2021-07-22 Barclays Overweight Maintains
2021-07-21 Raymond James Outperform Maintains
2021-07-21 Oppenheimer Outperform Maintains
2021-07-21 Mizuho Buy Maintains
2021-07-21 Deutsche Bank Buy Maintains
2021-07-21 Credit Suisse Outperform Maintains
2021-07-21 Citigroup Neutral Maintains
2021-07-19 Goldman Sachs Buy Maintains
2021-07-09 Seaport Global Buy Initiate
2021-04-26 Citigroup Buy Neutral Downgrade
2021-04-26 BMO Capital Market Perform Maintains
2021-04-23 RBC Capital Outperform Maintains
2021-04-23 Raymond James Outperform Reiterate
2021-04-23 Mizuho Buy Maintains
2021-04-23 Deutsche Bank Buy Maintains
2021-04-14 Truist Securities Buy Maintains
2021-04-13 Deutsche Bank Buy Maintains
2021-04-09 Mizuho Buy Maintains
2021-02-05 Mizuho Buy Maintains
2021-02-03 Raymond James Outperform Maintains
2021-02-03 Credit Suisse Outperform Maintains
2020-12-14 JP Morgan Neutral Overweight Upgrade
2020-10-27 Raymond James Outperform Maintains
2020-10-27 Piper Sandler Neutral Maintains
2020-10-27 Mizuho Buy Maintains
2020-10-27 Credit Suisse Outperform Maintains
2020-10-09 Credit Suisse Outperform Maintains
2020-09-21 JP Morgan Overweight Neutral Downgrade
2020-09-16 Truist Securities Buy Maintains
2020-07-23 Raymond James Outperform Maintains
2020-07-23 Piper Sandler Neutral Maintains
2020-07-23 Mizuho Buy Maintains
2020-07-13 BMO Capital Outperform Market Perform Downgrade
2020-06-11 UBS Buy Maintains
2020-05-20 Citigroup Buy Maintains
2020-04-27 UBS Buy Maintains
2020-04-22 SunTrust Robinson Humphrey Buy Maintains
2020-04-22 Barclays Overweight Maintains
2020-04-20 Raymond James Outperform Maintains
2020-04-13 SunTrust Robinson Humphrey Buy Maintains
2020-01-29 Stephens & Co. Overweight Maintains
2020-01-29 RBC Capital Outperform Maintains
2020-01-29 Credit Suisse Outperform Maintains
2020-01-29 Citigroup Buy Maintains
2020-01-29 Baird Outperform Maintains
2019-12-20 JP Morgan Overweight Maintains
2019-12-06 Bank of America Neutral Buy Upgrade
2019-11-20 Bank of America Neutral Reiterate
2019-10-30 UBS Buy Maintains
2019-10-30 Citigroup Buy Maintains
2019-10-30 Baird Outperform Maintains
2019-09-06 Bank of America Underperform Neutral Upgrade
2019-07-10 Goldman Sachs Neutral Buy Upgrade
2019-06-24 UBS Buy Maintains
2019-05-01 UBS Buy Buy Maintains
2019-05-01 Deutsche Bank Buy Buy Maintains
2019-04-23 Raymond James Market Perform Outperform Upgrade
2019-04-17 Barclays Overweight Overweight Maintains
2019-01-14 Stephens & Co. Overweight Initiate
2019-01-03 Deutsche Bank Buy Initiate
2018-11-16 UBS Buy Initiate
2018-11-06 Argus Buy Buy Maintains
2018-11-01 Credit Suisse Outperform Outperform Maintains
2018-10-31 Jefferies Buy Buy Maintains
2018-10-12 Citigroup Buy Buy Maintains
2018-10-11 Citigroup Buy Buy Maintains
2018-09-18 Bank of America Underperform Underperform Maintains
2018-09-05 Morgan Stanley Underweight Underweight Maintains
2018-09-05 BMO Capital Outperform Outperform Maintains
2018-09-04 Leerink Swann Outperform Outperform Maintains
2018-08-16 Morgan Stanley Underweight Underweight Maintains
2018-08-14 Barclays Overweight Initiate
2018-07-27 Credit Suisse Outperform Outperform Maintains
2018-07-13 Morgan Stanley Underweight Underweight Maintains
2018-02-01 Morgan Stanley Underweight Underweight Maintains
2018-02-01 BMO Capital Outperform Outperform Maintains
2018-01-31 Wells Fargo Outperform Outperform Maintains
2018-01-31 Leerink Swann Outperform Outperform Maintains
2018-01-31 Credit Suisse Outperform Outperform Maintains
2018-01-04 Bank of America Neutral Underperform Downgrade
2018-01-03 PiperJaffray Overweight Neutral Downgrade
2017-12-20 Morgan Stanley Equal-Weight Underweight Downgrade
2017-11-30 JP Morgan Neutral Overweight Upgrade
2017-11-21 William Blair Market Perform Initiate
2017-11-02 Credit Suisse Outperform Initiate
2017-11-01 Jefferies Buy Maintains
2017-10-19 BMO Capital Outperform Maintains
2017-10-19 Bank of America Neutral Maintains
2017-10-19 Baird Outperform Maintains
2017-10-17 BMO Capital Outperform Initiate
2017-10-13 Jefferies Buy Maintains
2017-08-22 Baird Outperform Maintains
2017-08-17 Morgan Stanley Equal-Weight Maintains
2017-08-14 Argus Buy Maintains
2017-07-26 Morgan Stanley Equal-Weight Maintains
2017-07-26 Citigroup Neutral Maintains
2017-07-26 Bank of America Buy Neutral Downgrade
2017-06-28 Argus Research Buy Initiate
2017-06-28 Argus Buy Initiate
2017-06-07 Morgan Stanley Equal-Weight Initiate
2017-06-07 Leerink Swann Market Perform Outperform Upgrade
2017-04-05 Deutsche Bank Buy Initiate
2017-03-27 Mizuho Neutral Buy Upgrade
2017-01-04 PiperJaffray Overweight Initiate
2016-11-09 Mizuho Buy Neutral Downgrade
2016-11-09 Avondale Partners Market Outperform Market Perform Downgrade
2016-10-13 KeyBanc Hold Overweight Upgrade
2016-09-30 Citigroup Neutral Maintains
2016-09-23 Evercore ISI Group Hold Initiate
2016-07-29 JP Morgan Overweight Neutral Downgrade
2016-07-29 Citigroup Neutral Maintains
2016-06-16 Bernstein Market Perform Initiate
2016-04-15 Avondale Partners Market Outperform Maintains
2016-03-24 Credit Suisse Outperform Maintains
2016-03-14 JP Morgan Neutral Overweight Upgrade
2016-01-29 Credit Suisse Outperform Maintains
2016-01-06 Longbow Research Outperform Market Perform Downgrade
2016-01-06 Barclays Overweight Maintains
2016-01-04 Wells Fargo Outperform Market Perform Downgrade
2015-12-17 Goldman Sachs Buy Neutral Downgrade
2015-12-16 Credit Suisse Outperform Initiate
2015-10-28 Leerink Swann Outperform Maintains
2015-10-28 Cantor Fitzgerald Buy Maintains
2015-10-15 Jefferies Buy Maintains
2015-10-08 Barclays Overweight Maintains
2015-09-16 JP Morgan Neutral Initiate
2015-07-16 Barclays Overweight Maintains
2015-06-26 Wells Fargo Market Perform Outperform Upgrade
2015-06-26 Oppenheimer Outperform Maintains
2015-06-26 Jefferies Buy Maintains
2015-06-24 Leerink Swann Outperform Maintains
2015-06-10 Wedbush Outperform Initiate
2015-05-06 RBC Capital Outperform Maintains
2015-05-06 Credit Suisse Outperform Maintains
2015-04-16 Deutsche Bank Buy Maintains
2015-01-08 Credit Suisse Outperform Maintains
2015-01-08 Barclays Overweight Maintains
2015-01-05 Deutsche Bank Buy Maintains
2014-12-18 Sterne Agee Buy Initiate
2014-11-12 Wells Fargo Outperform Market Perform Downgrade
2014-10-29 Credit Suisse Outperform Maintains
2014-10-29 Citigroup Buy Maintains
2014-10-29 Barclays Overweight Maintains
2014-10-28 Barclays Overweight Maintains
2014-10-02 JP Morgan Overweight Maintains
2014-09-09 Deutsche Bank Buy Maintains
2014-07-30 UBS Buy Maintains
2014-07-30 Credit Suisse Outperform Maintains
2014-07-30 Citigroup Buy Maintains
2014-07-30 Barclays Overweight Maintains
2014-07-17 Raymond James Outperform Maintains
2014-07-17 Deutsche Bank Buy Maintains
2014-06-03 JP Morgan Overweight Maintains
2014-03-31 Monness Crespi Hardt Buy Initiate
2014-01-15 Raymond James Outperform Maintains
2013-11-13 BMO Capital Market Perform Maintains
2013-10-07 Deutsche Bank Buy Maintains
2013-09-18 Mizuho Neutral Buy Upgrade
2013-07-11 KeyBanc Hold Initiate
2013-05-13 BMO Capital Market Perform Maintains
2013-05-03 Credit Suisse Outperform Maintains
2013-03-25 JP Morgan Overweight Maintains
2013-03-22 Oppenheimer Outperform Maintains
2013-03-12 Macquarie Outperform Neutral Downgrade
2013-02-11 Morgan Stanley Overweight Initiate
2013-02-06 Credit Suisse Outperform Maintains
2013-02-06 BMO Capital Market Perform Maintains
2013-02-04 Jefferies Buy Maintains
2013-01-30 Deutsche Bank Buy Maintains
2013-01-25 UBS Buy Maintains
2013-01-17 Imperial Capital Outperform Maintains
2012-12-18 JP Morgan Overweight Initiate
2012-11-07 Goldman Sachs Neutral Buy Upgrade
2012-10-11 Barclays Overweight Initiate
2012-08-28 Cantor Fitzgerald Buy Maintains
2012-08-20 Imperial Capital Outperform Initiate
2012-08-07 Jefferies Buy Maintains
2012-08-06 Cantor Fitzgerald Buy Maintains
2012-05-04 Deutsche Bank Buy Maintains
2012-03-23 Cantor Fitzgerald Buy Initiate
2012-02-23 Deutsche Bank Buy Upgrade
2023-01-30 RBC Capital Outperform Maintains
2023-01-30 Cowen & Co. Outperform Maintains
2023-01-30 Citigroup Buy Maintains
2023-01-30 Truist Securities Buy Maintains
2023-01-30 Mizuho Buy Maintains
2023-01-31 Raymond James Outperform Maintains
2023-02-08 Goldman Sachs Buy Maintains
2023-02-22 Stephens & Co. Overweight Maintains
2023-02-13 Argus Research Buy Maintains
2023-02-23 JP Morgan Overweight Maintains
2023-01-03 Wells Fargo Equal-Weight Maintains
2023-03-13 Stephens & Co. Overweight Reiterate
2023-03-16 RBC Capital Outperform Reiterate
2023-04-19 JP Morgan Neutral Maintains
2023-04-11 Mizuho Buy Maintains
2023-04-21 Stephens & Co. Overweight Reiterate
2023-04-21 Cantor Fitzgerald Overweight Initiate
2023-04-24 Credit Suisse Outperform Maintains
2023-04-24 Oppenheimer Outperform Maintains
2023-04-24 Citigroup Buy Maintains
2023-05-16 Mizuho Buy Buy Maintains
2023-04-24 Truist Securities Buy Maintains
2023-04-24 Jefferies Buy Maintains
2023-04-24 Deutsche Bank Buy Maintains
2023-04-24 RBC Capital Outperform Maintains
2023-04-24 Raymond James Outperform Maintains
2023-04-24 B of A Securities Buy Maintains
2023-04-24 TD Cowen Outperform Maintains
2023-04-24 Loop Capital Buy Maintains
2023-04-25 Wells Fargo Equal-Weight Maintains
2023-04-25 Bernstein Outperform Maintains
2023-04-25 Barclays Equal-Weight Maintains
2023-05-10 Argus Research Buy Buy Maintains
2023-06-20 Truist Securities Buy Buy Maintains
2023-06-28 Barclays Equal-Weight Equal-Weight Maintains
2023-11-10 Stephens & Co. Overweight Overweight Reiterate
2023-09-13 RBC Capital Outperform Outperform Reiterate
2023-10-26 Wells Fargo Equal-Weight Equal-Weight Maintains
2023-10-25 Citigroup Buy Buy Maintains
2023-10-25 Stephens & Co. Overweight Overweight Maintains
2023-10-25 RBC Capital Outperform Outperform Maintains
2023-10-25 Mizuho Buy Buy Maintains
2023-10-25 Truist Securities Buy Buy Maintains
2023-07-11 Mizuho Buy Buy Maintains
2023-09-14 Cantor Fitzgerald Overweight Overweight Reiterate
2023-12-11 Goldman Sachs Buy Neutral Downgrade
2023-10-30 Goldman Sachs Buy Buy Maintains
2024-01-24 Raymond James Outperform Outperform Maintains
2023-07-28 Credit Suisse Outperform Outperform Maintains
2023-07-28 Oppenheimer Outperform Outperform Maintains
2023-10-20 Wells Fargo Equal-Weight Equal-Weight Maintains
2023-10-25 Raymond James Outperform Outperform Maintains
2024-01-31 RBC Capital Outperform Outperform Maintains
2024-01-31 Truist Securities Buy Buy Maintains
2024-01-31 Raymond James Outperform Outperform Maintains
2023-11-17 JP Morgan Neutral Neutral Maintains
2024-01-19 Cantor Fitzgerald Overweight Overweight Reiterate
2024-01-04 Bernstein Outperform Market Perform Downgrade
2024-05-30 JP Morgan Neutral Neutral Maintains
2024-05-30 Baird Outperform Initiate
2024-04-12 Deutsche Bank Buy Buy Maintains
2024-03-05 Cantor Fitzgerald Overweight Overweight Reiterate
2024-04-29 RBC Capital Outperform Outperform Maintains
2024-04-29 Oppenheimer Outperform Outperform Maintains
2024-01-17 Oppenheimer Outperform Outperform Reiterate
2024-04-29 Barclays Overweight Overweight Maintains
2024-04-30 TD Cowen Buy Buy Maintains
2024-03-06 Barclays Overweight Initiate
2024-03-28 Wells Fargo Equal-Weight Equal-Weight Maintains
2024-04-10 Cantor Fitzgerald Overweight Overweight Reiterate
2024-07-10 Barclays Overweight Overweight Maintains
2024-07-10 Cantor Fitzgerald Overweight Overweight Reiterate
2024-07-02 Cantor Fitzgerald Overweight Overweight Reiterate
2024-06-28 Deutsche Bank Buy Buy Maintains
2024-07-09 Cantor Fitzgerald Overweight Overweight Reiterate
2024-07-30 Wells Fargo Equal-Weight Equal-Weight Maintains
2025-01-27 Barclays Overweight Overweight Maintains
2025-01-27 Cantor Fitzgerald Overweight Overweight Reiterate
2025-04-15 Baird Outperform Neutral Downgrade
2025-01-27 B of A Securities Buy Buy Maintains
2025-01-27 RBC Capital Outperform Outperform Maintains
2024-08-14 UBS Buy Buy Maintains
2024-07-24 Leerink Partners Outperform Outperform Maintains
2024-07-24 Barclays Overweight Overweight Maintains
2024-07-24 RBC Capital Outperform Outperform Maintains
2024-07-24 Cantor Fitzgerald Overweight Overweight Reiterate
2024-07-24 Oppenheimer Outperform Outperform Maintains
2024-07-24 Truist Securities Buy Buy Maintains
2024-09-03 Morgan Stanley Equal-Weight Initiate
2025-07-16 Truist Securities Buy Buy Maintains
2024-11-22 Raymond James Outperform Market Perform Downgrade
2024-11-08 Barclays Overweight Overweight Maintains
2024-12-17 Morgan Stanley Equal-Weight Equal-Weight Maintains
2024-10-11 Keybanc Overweight Initiate
2024-07-25 Cantor Fitzgerald Overweight Overweight Maintains
2024-10-22 Wells Fargo Equal-Weight Equal-Weight Maintains
2024-08-23 RBC Capital Outperform Outperform Maintains
2024-11-06 Wells Fargo Equal-Weight Equal-Weight Maintains
2024-08-19 Cantor Fitzgerald Overweight Overweight Reiterate
2024-08-19 Truist Securities Buy Buy Maintains
2024-10-04 Cantor Fitzgerald Overweight Overweight Reiterate
2025-08-14 Baird Neutral Neutral Maintains
2024-11-25 Wells Fargo Equal-Weight Underweight Downgrade
2025-01-06 Truist Securities Buy Buy Maintains
2024-08-20 Cantor Fitzgerald Overweight Overweight Reiterate
2025-08-14 Wells Fargo Equal-Weight Equal-Weight Maintains
2024-10-28 TD Cowen Buy Buy Maintains
2024-10-28 Oppenheimer Outperform Outperform Maintains
2024-10-28 Keybanc Overweight Overweight Maintains
2024-10-01 Cantor Fitzgerald Overweight Overweight Reiterate
2025-01-07 Keybanc Overweight Overweight Maintains
2025-05-29 Wells Fargo Underweight Equal-Weight Upgrade
2025-04-09 Guggenheim Neutral Initiate
2025-06-02 Barclays Overweight Overweight Maintains
2025-04-28 RBC Capital Outperform Outperform Maintains
2025-06-09 Morgan Stanley Equal-Weight Equal-Weight Maintains
2025-07-28 Wolfe Research Outperform Peer Perform Downgrade
2025-07-16 B of A Securities Buy Neutral Downgrade
2025-06-23 RBC Capital Outperform Outperform Maintains
2025-07-28 Morgan Stanley Equal-Weight Equal-Weight Maintains
2025-07-28 RBC Capital Outperform Outperform Maintains
2025-07-28 Barclays Overweight Overweight Maintains
2025-08-04 JP Morgan Neutral Neutral Maintains
2025-08-26 Cantor Fitzgerald Overweight Overweight Reiterate
Revenue Estimates

The forecasted annual revenue of HCA Healthcare, Inc. in 2031-12-31 is 100,339MM. )

Understanding a company’s revenue history gives investors a snapshot of its potential growth. Revenue growth is a solid predictor of earnings (or profit) growth. A company that can increase its revenue while keeping its operating costs constant has more available capital to reinvest into its business or return to shareholders through dividends or share buybacks.

However, investors should be careful before investing in a company that is growing revenue but showing declining earnings or is unprofitable. In some cases, this is simply a case of a young company that is still in an early growth phase. But if this is a mature company, it can indicate that other fundamental problems exist.

How to Interpret Revenue Estimates?

Fintel gives you revenue projections for stocks that cover 10 years between 2020 and 2030. Although past performance does not guarantee future results, you can be more confident in your decision to buy or sell a stock when you see a company with revenue that has a track record of increasing its revenue.

Update Frequency: Quarterly

Date Revenue Average Quarterly (MM) Number of Analysts (Quarterly) Revenue Average Annually (MM) Number of Analysts (Annually)
2025-09-30 17,782 3 -- --
2025-12-31 18,357 3 68,029 15
2026-03-31 18,297 2 -- --
2026-06-30 18,445 2 -- --
2026-09-30 18,857 2 -- --
2026-12-31 20,343 5 68,361 15
2027-12-31 -- -- 81,682 4
2028-12-31 -- -- 82,943 2
2029-12-31 -- -- 87,401 2
2030-12-31 -- -- 93,248 2
2031-12-31 -- -- 100,339 2
Earnings Estimates

The forecasted annual earnings of HCA Healthcare, Inc. in 2032-12-31 is 52.54 per share.

One part of an analyst’s rating is a profit (i.e., earnings) estimate for the current quarter and/or future quarters. The measurement given is earnings per share (EPS). EPS is a metric that indicates how much a company earned as represented by one share of its stock over a specific period (typically three months).

Earnings per Share Calculation

To understand the earnings per share calculation, you must understand net income. Net income is the amount of money a company has left over after deducting appropriate expenses and taxes from its revenues).

The formula for earnings per share is net income divided by the total number of outstanding shares (i.e., available for purchase). For example:

Company A has a net income of $100 million and forty million outstanding shares. The EPS calculation is as follows:

100,000,000/40,000,000 = $2.50 per share

How to use Earnings Per Share in Stock Analysis

Earnings per share is an essential metric for you to consider when deciding to buy a stock. After all, a company with high earnings per share is productive and generates revenue in excess of its operating costs.

However, it’s not the only metric you should use. Metrics like price-to-earnings and debt-to-equity add additional perspective about a company’s health.

You should also be sure to compare a company’s EPS with a company in its sector. However, when you do, be aware that EPS is different and more important than net profit by itself. You may see a company that has a rising net profit. But if its outstanding shares are also rising, then its EPS might be flat or even edging lower.

Update Frequency: Quarterly

Date EPS Average (Quarterly) Number of Analysts (Quarterly) EPS Average (Annual) Number of Analysts (Annually)
2025-09-30 5.16 3 -- --
2025-12-31 6.27 3 22.80 16
2026-03-31 6.66 2 -- --
2026-06-30 6.56 2 -- --
2026-09-30 5.63 2 -- --
2026-12-31 7.91 5 25.14 16
2027-03-31 7.59 3 -- --
2027-06-30 8.12 3 -- --
2027-09-30 7.33 3 -- --
2027-12-31 9.29 3 29.89 4
2028-12-31 -- -- 29.77 2
2029-12-31 -- -- 32.03 2
2030-12-31 -- -- 35.23 2
2031-12-31 -- -- 39.40 2
2032-12-31 -- -- 52.54 2
EBITDA Estimates

The forecasted annual EBITDA of HCA Healthcare, Inc. in 2028-12-31 is 16,940MM.

EBIDTA is an acronym that stands for earnings before interest, taxes, depreciation, and amortization. Analysts and investors pay attention to EBITDA because it strips out items that a company must report on its balance sheet but doesn’t significantly impact its business. Here’s an explanation of what that means for each part of the acronym:

Interest: Loan interest and earnings are subject to change based on a company’s financial strategy and, in any event, are not part of its core activities.

Taxes: Taxes are affected by governmental policy that can distort a company’s perceived profitability.

Depreciation: This accounts for the expected depreciation on tangible assets and immaterial goods from company investments. But since these investments may ultimately increase a company’s efficiency and profit potential, they aren’t a good indicator of a company’s current profitability.

Amortization: This shows the gradual writing off of the initial cost of an asset. It differs from depreciation because it is typically used with intangible assets such as intellectual property (e.g., patents, copyrights, etc.)

EBITDA vs. Net Income

Net income is the profit a company has left over after covering its operating expenses. However, net income includes the items that EBITDA excludes. That’s why most analysts prefer EBITDA because it better reflects the health of a company’s core business.

Update Frequency: Quarterly

Date EBITDA Average (MM Quarterly) Number of Analysts (Quarterly) EBITDA Average (MM Annually) Number of Analysts (Annually)
2025-09-30
2025-12-31
2026-03-31
2026-06-30
2026-09-30
2026-12-31
2027-12-31
2028-12-31
EBIT Estimates

The forecasted annual EBIT of HCA Healthcare, Inc. in 2028-12-31 is 12,810MM.

EBIT is an acronym that stands for earnings before interest and taxes. Analysts use EBIT to measure a company’s performance because it strips out tax expenses and the costs of the capital structure influencing profit. These don’t significantly impact a company’s business.

Interest: Loan interest and earnings are subject to change based on a company’s financial strategy and, in any event, are not part of its core activities.

Taxes: Taxes are affected by governmental policy that can distort a company’s perceived profitability.

NOTE: EBIT is sometimes synonymous with operating income. However, in some cases, operating income doesn’t include gains or losses from non-core activities.

EBIT vs. EBITDA

EBITDA also strips out depreciation and amortization from a company’s earnings:

Depreciation: This accounts for the expected depreciation on tangible assets and immaterial goods from company investments. But since these investments may ultimately increase a company’s efficiency and profit potential, they aren’t a good indicator of a company’s current profitability.

Amortization: This shows the gradual writing off of the initial cost of an asset. It differs from depreciation because it is typically used with intangible assets such as intellectual property (e.g., patents, copyrights, etc.)

Update Frequency: Quarterly

Date EBIT Average (MM Quarterly) Number of Analysts (Quarterly) EBIT Average (MM Annually) Number of Analysts (Annually)
2025-09-30
2025-12-31
2026-03-31
2026-06-30
2026-09-30
2026-12-31
2027-12-31
2028-12-31
Other Listings
MX:HCA
IT:1HCA €350.00
GB:0J1R $412.74
DE:2BH €352.70
Fintel data has been cited in the following publications:
Daily Mail Fox Business Business Insider Wall Street Journal The Washington Post Bloomberg Financial Times Globe and Mail
NASDAQ.com Reuters The Guardian Associated Press FactCheck.org Snopes Politifact
Federal Register The Intercept Forbes Fortune Magazine TheStreet Time Magazine Canadian Broadcasting Corporation International Business Times
Cambridge University Press Investopedia MarketWatch NY Daily News Entrepreneur Newsweek Barron's El Economista